Rapport Therapeutics Past Earnings Performance
Past criteria checks 0/6
Rapport Therapeutics's earnings have been declining at an average annual rate of -172.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Key information
-172.7%
Earnings growth rate
16.7%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | -18.7% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Rapport Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -63 | 15 | 48 |
31 Mar 24 | 0 | -51 | 11 | 37 |
31 Dec 23 | 0 | -35 | 8 | 28 |
Quality Earnings: RAPP is currently unprofitable.
Growing Profit Margin: RAPP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if RAPP's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare RAPP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAPP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: RAPP has a negative Return on Equity (-18.71%), as it is currently unprofitable.